Novavax (NASDAQ: NVAX) reported Q1 EPS of ($0.14), $0.01 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $9.7 million versus the consensus estimate of $9.33 million.

For earnings history and earnings-related data on Novavax (NVAX) click here.